🚀 VC round data is live in beta, check it out!
Anthem Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Anthem Biosciences and similar public comparables like Humanwell Healthcare, GSK India, LigaChem Biosciences, Peptron and more.
Anthem Biosciences Overview
About Anthem Biosciences
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
Founded
2006
HQ
Employees
2.1K
Website
Sectors
Financials (LTM)
EV
$4B
Anthem Biosciences Financials
Anthem Biosciences reported last 12-month revenue of $228M and EBITDA of $88M.
In the same LTM period, Anthem Biosciences generated $138M in gross profit, $88M in EBITDA, and $63M in net income.
Revenue (LTM)
Anthem Biosciences P&L
In the most recent fiscal year, Anthem Biosciences reported revenue of $216M and EBITDA of $82M.
Anthem Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $228M | XXX | $216M | XXX | XXX | XXX |
| Gross Profit | $138M | XXX | $119M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $88M | XXX | $82M | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $63M | XXX | $53M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 24% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Anthem Biosciences Stock Performance
Anthem Biosciences has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Anthem Biosciences' stock price is $7.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 4.9% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnthem Biosciences Valuation Multiples
Anthem Biosciences trades at 18.7x EV/Revenue multiple, and 48.8x EV/EBITDA.
EV / Revenue (LTM)
Anthem Biosciences Financial Valuation Multiples
As of April 11, 2026, Anthem Biosciences has market cap of $4B and EV of $4B.
Equity research analysts estimate Anthem Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anthem Biosciences has a P/E ratio of 69.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 18.7x | XXX | 19.8x | XXX | XXX | XXX |
| EV/EBITDA | 48.8x | XXX | 52.2x | XXX | XXX | XXX |
| EV/EBIT | 57.7x | XXX | 62.8x | XXX | XXX | XXX |
| EV/Gross Profit | 31.0x | XXX | 35.9x | XXX | XXX | XXX |
| P/E | 69.2x | XXX | 82.9x | XXX | XXX | XXX |
| EV/FCF | 220.5x | XXX | 237.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Anthem Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Anthem Biosciences Margins & Growth Rates
Anthem Biosciences' revenue in the last 12 month grew by 21%.
Anthem Biosciences' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Anthem Biosciences' rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anthem Biosciences' rule of X is 87% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Anthem Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 87% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Anthem Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Humanwell Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| LigaChem Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| Beijing Tiantan | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anthem Biosciences M&A Activity
Anthem Biosciences acquired XXX companies to date.
Last acquisition by Anthem Biosciences was on XXXXXXXX, XXXXX. Anthem Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Anthem Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnthem Biosciences Investment Activity
Anthem Biosciences invested in XXX companies to date.
Anthem Biosciences made its latest investment on XXXXXXXX, XXXXX. Anthem Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Anthem Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Anthem Biosciences
| When was Anthem Biosciences founded? | Anthem Biosciences was founded in 2006. |
| Where is Anthem Biosciences headquartered? | Anthem Biosciences is headquartered in India. |
| How many employees does Anthem Biosciences have? | As of today, Anthem Biosciences has over 2K employees. |
| Who is the CEO of Anthem Biosciences? | Anthem Biosciences' CEO is Ajay Bhardwaj. |
| Is Anthem Biosciences publicly listed? | Yes, Anthem Biosciences is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Anthem Biosciences? | Anthem Biosciences trades under ANTHEM ticker. |
| When did Anthem Biosciences go public? | Anthem Biosciences went public in 2025. |
| Who are competitors of Anthem Biosciences? | Anthem Biosciences main competitors are Humanwell Healthcare, GSK India, LigaChem Biosciences, Peptron. |
| What is the current market cap of Anthem Biosciences? | Anthem Biosciences' current market cap is $4B. |
| What is the current revenue of Anthem Biosciences? | Anthem Biosciences' last 12 months revenue is $228M. |
| What is the current revenue growth of Anthem Biosciences? | Anthem Biosciences revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Anthem Biosciences? | Current revenue multiple of Anthem Biosciences is 18.7x. |
| Is Anthem Biosciences profitable? | Yes, Anthem Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Anthem Biosciences? | Anthem Biosciences' last 12 months EBITDA is $88M. |
| What is Anthem Biosciences' EBITDA margin? | Anthem Biosciences' last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of Anthem Biosciences? | Current EBITDA multiple of Anthem Biosciences is 48.8x. |
| What is the current FCF of Anthem Biosciences? | Anthem Biosciences' last 12 months FCF is $19M. |
| What is Anthem Biosciences' FCF margin? | Anthem Biosciences' last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Anthem Biosciences? | Current FCF multiple of Anthem Biosciences is 220.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.